Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

UNO Technologies announces collaboration with Aetos Pharma to further accelerate Malaysia's healthcare tech transformation

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- UNO Technologies, a rapidly growing Medical Technology ("med tech") firm based inSingapore, has recently announced its expansion into the Malaysian market. As part of its regional strategy, UNO will team up with Aetos Pharma, a burgeoning Malaysian pharmac...

2021-10-21 12:38 2300

UNO Technologies announces collaboration with Aetos Pharma to further accelerate Malaysia's healthcare tech transformation

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...

2021-10-21 10:31 2225

Singapore-based Biosyngen receives 500 million yuan in investment

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- At the 12th Singapore-Guangdong Collaboration Council (SGCC) meeting held online onOctober 20, Singapore-based Biosyngen Pte. Ltd. ("Biosyngen") announced its partnership with wholly state-owned Chinese company Science City (Guangzhou) Investment Group Co....

2021-10-21 09:30 4108

Singapore-based Biosyngen receives 500 million yuan in investment

A Hypercompact CRISPR Technology Developed by GenKOre is deemed a Potential Game Changer in Gene Therapy.

DAEJEON, South Korea, Oct. 20, 2021 /PRNewswire/ -- On September 2, 2021, a scientific paper from GenKOre on the new hypercompact CRISPR system called CRISPR/Cas12f-GE was published in an online issue of Nature Biotechnology (IF 54.9), one of the world's top-tier biotechnology journals.

2021-10-21 09:05 1272

A Hypercompact CRISPR Technology Developed by GenKOre is deemed a Potential Game Changer in Gene Therapy.

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 1670

EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization

CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, andIntouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreemen...

2021-10-20 22:34 2978

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 4000

Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

* Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. * Statistically significant 114% faster time to reach EQ-5D-5L Q6 ≥ 90% versus SOC/best supportive care. * Statistically significant 57% faster time to norm...

2021-10-20 20:52 1577

Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

Seoul Gangnam-gu kicks off 2021 Medical Tourism Brand Festa

SEOUL, South Korea, Oct. 20, 2021 /PRNewswire/ -- Gangnam-gu (the Mayor of Gangnam-gu, Jeong sungun) is holdiong the '2021 Gangnam Medical Festa' in Nonhyeon-ro and Sinsa-ro areas for the month of October with the theme of 'Gangnam connected to the world, Gangnam, a healthy medical city'.

2021-10-20 20:05 1614

Island Pharmaceuticals to discuss its potential dengue fever preventative at Pharma Meeting Brazil & Latam 2021

MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to be attending Pharma Meeting Brazil & Latam 2021, this week and presenting to potential partners. Island's attendance at the co...

2021-10-20 18:00 1292

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- HistoIndex , a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis an...

2021-10-20 18:00 1452

Xinhua Silk Road: 52nd Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi

BEIJING, Oct. 20, 2021 /PRNewswire/ -- The 52nd Zhangshu National Traditional Chinese Materia MedicaTrade Fair opened in Zhangshu, a country-level city in eastChina's Jiangxi Province on Saturday.

2021-10-20 17:27 2172

Xinhua Silk Road: 52nd Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi

A Hypercompact CRISPR Technology Developed by GenKOre is deemed a Potential Game Changer in Gene Therapy.

2021-10-20 15:31 1961

Getinge Q3 Report 2021: "Strong order intake and our remediation measures completed in Germany"

GOTHENBURG, Sweden, Oct. 20, 2021 /PRNewswire/ -- "Organic order intake increased by more than 20% in the third quarter, with a strong performance in all business areas and regions," says Mattias Perjos, President & CEO at Getinge. "Our cash flow remains strong, meaning that we have strengthened ...

2021-10-20 15:19 3199

Action for bone health is needed now more than ever, urges IOF

NYON, Switzerland, Oct. 20, 2021 /PRNewswire/ -- A backlog in osteoporosis assessments, treatment delays, and sedentary indoor lifestyles: these are just several ways in which the Covid-19 pandemic has impacted bone health and disrupted global osteoporosis care. Osteoporosis is a common bone dis...

2021-10-20 13:30 1826

Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources

Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines SEATTLE, Oct. 20, 2021 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today a comm...

2021-10-20 13:29 1827

Phillips-Medisize Increases Global Manufacturing Capacity, Capabilities and Collaborations to Drive Drug Delivery, Diagnostic and MedTech Innovations

- Medical and pharmaceutical solutions leader poised to scale manufacturing from new and expanded production facilities and R&D centers inPoland, China and U.S. - End-to-end capabilities optimize design, development and manufacturing of world-class healthcare products and solutions while reducin...

2021-10-20 10:00 2173

Phillips-Medisize Increases Global Manufacturing Capacity, Capabilities and Collaborations to Drive Drug Delivery, Diagnostic and MedTech Innovations

CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC

SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (...

2021-10-20 08:00 2519

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China

* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seeks to accelerate its business development activities with Daewoong, their partner for the development and commercialization of BBT-401 in 22 Asian countries SEONGNAM, South Korea and CHENGDU, China, ...

2021-10-20 07:00 1223

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...

2021-10-20 05:08 1484

1 ... 328 329 330331332 333 334 ... 578